These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 22112541

  • 1. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity.
    Li HQ, Li DD, Lu X, Xu YY, Zhu HL.
    Bioorg Med Chem; 2012 Jan 01; 20(1):317-23. PubMed ID: 22112541
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity.
    Xu YY, Cao Y, Ma H, Li HQ, Ao GZ.
    Bioorg Med Chem; 2013 Jan 15; 21(2):388-94. PubMed ID: 23245570
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
    Abouzid K, Shouman S.
    Bioorg Med Chem; 2008 Aug 15; 16(16):7543-51. PubMed ID: 18678492
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
    Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C.
    J Med Chem; 2010 Mar 11; 53(5):2000-9. PubMed ID: 20143778
    [Abstract] [Full Text] [Related]

  • 9. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 10. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S, Narla RK, Zheng Y, Liu XP, Jun X, Mao C, Sudbeck EA, Uckun FM.
    Anticancer Drug Des; 1999 Oct 15; 14(5):403-10. PubMed ID: 10766295
    [Abstract] [Full Text] [Related]

  • 11. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
    Ahmed MF, Magdy N.
    Anticancer Agents Med Chem; 2017 Oct 15; 17(6):832-838. PubMed ID: 27671305
    [Abstract] [Full Text] [Related]

  • 12. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ.
    J Med Chem; 1999 May 20; 42(10):1803-15. PubMed ID: 10346932
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
    Mowafy S, Farag NA, Abouzid KA.
    Eur J Med Chem; 2013 Mar 20; 61():132-45. PubMed ID: 23142066
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
    Zhang H, Lu X, Zhang LR, Liu JJ, Yang XH, Wang XM, Zhu HL.
    Bioorg Med Chem; 2012 Feb 15; 20(4):1411-6. PubMed ID: 22277588
    [Abstract] [Full Text] [Related]

  • 15. Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.
    Yang W, Hu Y, Yang YS, Zhang F, Zhang YB, Wang XL, Tang JF, Zhong WQ, Zhu HL.
    Bioorg Med Chem; 2013 Mar 01; 21(5):1050-63. PubMed ID: 23391364
    [Abstract] [Full Text] [Related]

  • 16. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW, Xu GJ, Wang J, Jiang XL, Li HB.
    ChemMedChem; 2013 Jun 01; 8(6):928-33. PubMed ID: 23640754
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y, Li HY, Lin LP, Tan J, Ding J, Luo X, Long YQ.
    Bioorg Med Chem; 2005 Oct 01; 13(19):5613-22. PubMed ID: 15993078
    [Abstract] [Full Text] [Related]

  • 18. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.
    Antonello A, Tarozzi A, Morroni F, Cavalli A, Rosini M, Hrelia P, Bolognesi ML, Melchiorre C.
    J Med Chem; 2006 Nov 16; 49(23):6642-5. PubMed ID: 17154492
    [Abstract] [Full Text] [Related]

  • 19. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Zhang Y, Chen L, Xu H, Li X, Zhao L, Wang W, Li B, Zhang X.
    Eur J Med Chem; 2018 Mar 10; 147():77-89. PubMed ID: 29421573
    [Abstract] [Full Text] [Related]

  • 20. Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.
    Li S, Sun X, Zhao H, Tang Y, Lan M.
    Bioorg Med Chem Lett; 2012 Jun 15; 22(12):4004-9. PubMed ID: 22595177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.